Diagnostic Computed Tomography Coregistration With In-111-DTPA-Octreotide Single Photon Emission Tomography/Low-Dose...

Area of Science:

• Nuclear Medicine
• Radiology
• Oncology

Background:

• Indium-111 DTPA-octreotide (OctreoScan) remains crucial for neuroendocrine tumor (NET) imaging.
• Low-dose CT (LDCT) aids SPECT localization but can lead to interpretation uncertainty.
• Ga-68 octreotide tracers are newer alternatives.

Purpose of the Study:

• To evaluate the impact of coregistering In-111 DTPA-octreotide SPECT/LDCT with diagnostic CT.
• To assess how this coregistration affects the interpretation of somatostatin receptor presence in NETs.

Main Methods:

• Retrospective analysis of 35 NET imaging studies with uncertain SPECT/LDCT interpretations.
• Coregistration of In-111 DTPA-octreotide SPECT/LDCT with diagnostic CT.
• Categorization of somatostatin receptor presence (definitely positive/negative, probably positive/negative) before and after coregistration.

Main Results:

• Coregistration was performed on 35 studies; 31 were analyzed after excluding 4 definite cases.
• Interpretation changed from uncertain to definite in 30 of 31 cases (97%).
• Diagnosis shifted from probably positive to definitely negative in 13 of 23 cases; greatest benefits seen in liver, pancreas, and lymph nodes.

Conclusions:

• Coregistration of SPECT/LDCT with diagnostic CT enhances diagnostic certainty in neuroendocrine tumor imaging.
• This technique is increasingly accessible and valuable for inconclusive SPECT/LDCT findings.